CR Double-Crane Pharmaceutical's Unit Completes Registration of Phase III Trial of Pregabalin Tablets
MT Newswires Live
Aug 07
China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, China Resources Double-Crane Limin Pharmaceutical (Jinan), completed the registration of its phase III clinical trial for pregabalin extended-release tablets, according to a Shanghai bourse filing on Friday.
The study found that the drug provides definite pain relief for patients with postherpetic neuralgia and its efficacy remained stable during long-term treatment. It also improved patients' sleep.
However, short-term improvements in anxiety, depression, and rescue medication use were not particularly evident.
The pharmaceutical company's shares rose 2% at the close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.